TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07743580: A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease

Sponsor: Shionogi · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 2000 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,089,352

Rescue Site Savings

+$2,045,652

Unlock Full NCT07743580 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07743580 Rescue Dossier →